Menu

Menarini Quality

About Us » Success Stories

Success Stories

Plan for success

With 25 years of experience, we’ve achieved a lot that we’re proud of. Read about a couple of our recent successful projects and get in touch to find out how we can make your project the next success story.

Amediplase

Amediplase is a thrombolytic agent chimeric protein (a glycosylated recombinant protein constituted of parts of the Tissue Plasminogen Activator and Urokinase) and is renowned as one of the most difficult biologics to manufacture. We successfully completed the manufacture of Amediplase for Phase I/II and Phase III.

Manufacture of Amediplase for Phase I/II studies   

Manufacture of Amediplase for Phase III studies

Abagovomab

Abagovomab is an anti-idiotypic antibody that mimics the CA 125 receptor, which is over-expressed in ovarian cancer. We successfully developed this in a murine hybridoma and manufactured in a hollow fibre bioreactor.      

Manufacture of Abagovomab for Phase III studies and process validation.

Biosimilars

In 2010 Menarini Biotech began developing a biosimilars product that has entered phase I trials.

OBT & Menarini

OBT and Menarini established a strategic partnership in October 2012, covering the development and commercialization of five of OBT's proprietary antibody-based cancer therapies. Under the collaboration, Menarini Biotech contributes process development and cGMP manufacturing, for phase i, II & III clinical supply.

Currently Menarini Biotech is developing the manufacturing process and producing clinical batches of 2 antibodies:
MEN1112 Is a humanized, de-fucosylated monoclonal IgGl antibody directed against an antigen which is over expressed in blasts of Acute Myeloid leukemia. MEN1112 is currently in phase I clinical trial.
MEN 1309 is a human monoclonal antibody conjugated to a potent cytotoxic agent, maytansin derivative, against a membrane antigen which is over-expressed in many tumors such non-Hodgkin lymphoma (NHL) and solid tumors such a subtype of breast cancer.

Third party production

In 2013 Menarini Biotech began the process development and cGMP production of a Monoclonal Antibody in oncology for a non-disclosed partner.

AJ3

Ketoprofene Esterase - A recombinant enzyme for the enantiomeric resolution of Ketoprofene produced in E. coli.

Many development projects including:
  • Oncology
    Monoclonal antibodies (mAbs), bi-specific mAbs, chemical immuno-conjugates, human/mouse chimeric mAbs, immuno-toxins, human apoptosis modulators, plasmid DNA vaccines produced in hybridomas, engineered CHO cells and bacteria.
  • Inflammation
    Site directed mutagenesis of receptors involved in inflammation and pain for rational drug design.
  • Haematopoiesis
    Recombinant human cytokines produced in CHO cells.

We’d like your project to be our next big success story. Contact us to find out how

Menarini Biotech
All rights reserved 2014


Part of the Menarini Group

Privacy Policy

Cookie Settings

INFORMATION NOTICE PURSUANT TO THE APPLICABLE DATA PROTECTION LAW
Before contacting us please read and agree to the information notice

 

This information notice is provided pursuant to Section 13 of the Italian Legislative Decree No. 196/2003, as amended (the “Italian PDPA”) and applies to personal data voluntarily provided by users (“Data Subjects”) who use the services of the company website www.menarini-biotech.com (“Site”).
Data Controller and Data Processor
The Data Controller is Menarini Biotech s.r.l. (“Company”), with registered offices in Via Tito Speri, 12, 00040 Pomezia (Rome), Italy, Phone +39-06911841.
The Data Processor is the Head of Business Development Dept. of the Company.
Purposes and Methods of Data Processing
The Company may process personal data for the sole purpose of processing your requests and/or enquiries (including but not limited to, requests for technical assistance and for scientific and promotional information, and communications also of a commercial nature).
Moreover, with your optional consent, your data may be processed for commercial / promotional / marketing purposes. This includes providing you with promotional material and/or commercial information relating to the Company’s services by traditional methods (for example: hard copy mail, operator calls, etc.) and automated ones (for example: e-mail, fax, text messages, mobile and smartphone apps, social network accounts, (i.e. via Facebook or Twitter), etc.).
Your personal data are processed both in paper and in electronic form. Data are entered into the Company information system in compliance with the Italian PDPA and according to profiles of data security and confidentiality, in line with the principles of fair and legal data processing.
Pursuant to Section 11 of the Italian PDPA, data are retained for the time strictly necessary to achieve the specific purposes for which they were collected.
Type of Data Processed
Where marked by an asterisk [*] personal data are essential for the Company to process your requests and/or enquiries (i.e.: your requests for information and/or materials) or to contact you to follow up your queries. Refusal to provide data marked by an asterisk will prevent the Company from providing the services you may have requested. The provision of any other data is optional: refusal will not have any implication on your request.
Providing your personal data for marketing purposed as specified in the section “Purposes and Methods of Data Processing” is optional: your refusal to provide such data will not have any implication on your request.
Your consent to the processing of your personal data for commercial / promotional / marketing purposes is meant to include communications by traditional and automated methods, as above exemplified.
As per the use of cookies on the Site, please refer to the specific section of the Privacy Policy of the Site.
Access to your Personal Data
Your personal data will be accessible only to the personnel in charge of data processing within the Company. In relation to their duties, such personnel needs to process your data to manage your requests. Data may be disclosed to employees of the other companies of the Menarini Group for the same purposes as stated above and/or for administrative purposes, pursuant to Section 34, Paragraph 1, of the Italian PDPA.
Without prejudice for the provisions of the above paragraph, your personal data are not communicated to third parties, be it natural or legal persons, and they will not be disseminated in any other manner or form.
Rights of the Data Subjects
You may at any times exercise the rights established by Section 7 of the Italian PDPA, including your right to receive confirmation of the existence of your personal data within the Company, your right to check the content, the source and the accuracy of your data, and/or to request that your data are updated, erased and/or de-identified, if unlawfully processed, as well as your right to stop the processing of your data for any legitimate reasons.
Please be informed that, pursuant to the Italian PDPA, your right to stop the processing of your data for marketing purposes performed by automated methods is meant to be extended also to communications by traditional methods. However, you are also entitled to partially exercise your rights (i.e. exercising it towards the processing performed by automated methods only and leaving the traditional ones or vice versa).
At any times you may apply the Data Processor, in the person of the Head of the Business Development Dept. of the Company (at the above address, or by phone at: +39-06911841) to receive information on the processing of your personal data by the Company, to exercise the rights established by the Italian PDPA, as well as to receive the updated list of subjects to whom data are accessible.

Having read the above information notice concerning the processing of my personal data, I give consent to Menarini Biotech to process my personal data for the sole purpose of processing my requests, communications and/or enquiries.

I AGREE